Trial Search Results

A Pilot Study of 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer

The objective of the study is to evaluate 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for biopsy guidance in patients with suspected prostate cancer.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Andrei Iagaru

Collaborator: General Electric


  • Drug: 68Ga RM2
  • Drug: 68Ga-PSMA-11
  • Device: Investigational PET scanner coils and software


Phase 2


Inclusion Criteria:

   - Suspected prostate cancer

   - Planned prostate biopsy

   - Able to provide written consent

   - Karnofsky performance status of 50 (or ECOG/WHO equivalent)

Exclusion Criteria:

   - Patients not capable of getting PET study due to weight, claustrophobia, or inability
   to lay still for the duration of the exam

   - Metallic implants (contraindicated for MRI)

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Brittney Williams
Not Recruiting